CAMP4 Therapeutics to Present at Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 01, 2026 /CourierPR/ -- CAMP4 Therapeutics Corporation, a clinical-stage biopharmaceutical company focused on developing therapies to upregulate gene expression for genetic diseases, will participate in upcoming investor conferences. The company will present at these events, providing insights into its pipeline of regulatory RNA-targeting therapeutics designed to restore healthy protein levels.

CAMP4 will be available for investors to learn more about its RAP Platform, which aims to amplify mRNA by targeting regulatory RNAs (regRNAs). These regRNAs are master regulators of gene expression, and by harnessing them, CAMP4 is developing treatments for genetic diseases. The company’s approach involves targeting regRNAs with antisense oligonucleotide (ASO) drug candidates to enhance mRNA levels, potentially offering therapeutic benefits for a broad range of genetic conditions.

CAMP4’s pipeline includes treatments for over 1,200 genetic disorders characterized by haploinsufficiency and recessive partial loss-of-function disorders. By modestly increasing protein expression in these conditions, the company hopes to achieve clinically meaningful outcomes. The company’s proprietary platform allows for the mapping of regRNAs and the generation of targeted therapeutic candidates.

The presentations will provide further details on the progress of CAMP4’s research and development efforts, as well as updates on its clinical trials. Attendees will have the opportunity to engage with CAMP4’s team and gain a deeper understanding of the potential of its gene expression therapies.

For those unable to attend in person, the webcasts offer a convenient way to stay informed. CAMP4’s commitment to advancing treatments for genetic diseases is underscored by its participation in these investor conferences, providing a platform for investors and stakeholders to learn about the company’s latest developments.